# 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

> **NCT04023331** · PHASE1,PHASE2 · TERMINATED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 21 (actual)

## Conditions studied

- Neuroblastoma
- Relapsed Neuroblastoma
- Refractory Neuroblastoma

## Interventions

- **DRUG:** 67Cu-SARTATE
- **DRUG:** 64Cu-SARTATE

## Key facts

- **NCT ID:** NCT04023331
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-18
- **Primary completion:** 2025-01-24
- **Final completion:** 2025-03-25
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023331, "67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04023331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*